# 6MW3511 in Patients With Advanced Solid Tumor

> **NCT05524194** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 272 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Intravenous Infusion

## Key facts

- **NCT ID:** NCT05524194
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2024-06
- **Final completion:** 2024-09
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524194, "6MW3511 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05524194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*